Leading Chinese in-vitro diagnostics maker selling immunoassay and chemistry analyzers plus reagents to hospital labs.
Leading Chinese in-vitro diagnostics maker selling immunoassay and chemistry analyzers plus reagents to hospital labs.
Places analyzers in hospital labs and earns recurring revenue from the reagents consumed on every test, which carry more of the profit than the instrument. Hospital buying runs largely through public procurement and tenders.
In one line: A Chinese Abbott Diagnostics/Roche Diagnostics for IVD.
Moat: narrow (installed base, switching costs). Analyzer-reagent lock-in once a hospital lab adopts its instrument platform.
Headquarters: Zhengzhou, Henan, China · Founded: 1998 · Employees: 5,700
Size Autobio Diagnostics (603658.SS) is a China Health Care company (Medical Specialties) with a market value of $3.36B, the 724th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.82 on 18 Nov 2026.
Performance Over six months the shares gained 15.6%, against +3.2% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 2.9% over the last twelve months (peer median +7.4%); the operating margin is 25.4% (peer median 7.3%).
Valuation It trades at 20.3× forward earnings against a peer median of 27.2× (5th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.6 points above its cost of capital (5.1% WACC).
Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.34B | CN¥4.19B | CN¥4.44B | CN¥4.39B | CN¥4.40B |
| Revenue growth | — | -6% | +1% | 0% | — |
| Gross profit | CN¥3.21B | CN¥2.59B | CN¥2.76B | CN¥2.71B | CN¥2.49B |
| EBITDA | n/a | CN¥1.56B | CN¥1.61B | CN¥1.66B | CN¥1.58B |
| Net income | CN¥1.06B | CN¥1.07B | CN¥1.19B | CN¥1.22B | CN¥1.17B |
| Free cash flow | CN¥539M | CN¥738M | CN¥649M | CN¥569M | CN¥629M |
| Capital expenditure | CN¥494M | CN¥604M | CN¥664M | CN¥900M | CN¥938M |
| Total debt | CN¥972M | CN¥996M | CN¥1.04B | CN¥1.04B | CN¥873M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Autobio Diagnostics 603658.SS | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603658.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.5% | -0.2% | 5th highest of 21 |
| 6-month return | +15.6% | +3.2% | 10th highest of 21 |
| Distance from 52-week high | -3.3% | -24.1% | highest of 21 |
| Revenue growth (TTM) | +2.9% | +7.4% | 7th lowest of 21 |
| Operating margin | 25.4% | 7.3% | highest of 20 |
| Forward P/E | 20.3× | 27.2× | 5th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -0.4% | 12.6% | 4th least demanding of 17 |
| Growth delivered (Del g) | +7.2% | +9.5% | 7th lowest of 17 |
| Hurdle (Req g minus delivered) | -7.6 pp | +1.7 pp | 4th least demanding of 17 |
| ROIC minus cost of capital | +7.6 pp | -1.6 pp | 2nd highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |